Novel trends in the treatment of cardiovascular disorders: Site-and event-selective adenosinergic drugs

Current Medicinal Chemistry

Volumn 18, Issue 8, 2011, Pages 1164-1187

  Szentmiklosi A J ^a   Cseppento A ^a   Harmati, G ^a   Nanasi P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

5' nucleotidase; Adenosine deaminase; Adenosine kinase; Adenosine regulators; Adenosinergic drugs; Allosteric receptor modulators; AMP deaminase; Membrane adenosine transport; Site and event specific action

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 5 IODOTUBERCIDIN; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE DEAMINASE INHIBITOR; ADENOSINE KINASE INHIBITOR; ARISTEROMYCIN; COFORMYCIN; DIGOXIN; DIPYRIDAMOLE; LIDOFLAZINE; METHOTREXATE; NAXIFYLLINE; NITROBENZYLTHIOINOSINE; PLACEBO; ROLOFYLLINE; SOLUFLAZINE; THEOPHYLLINE; TROGLITAZONE; TUBERCIDIN; VERAPAMIL;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; BRADYCARDIA; BURNING SENSATION; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY BLOOD FLOW; DRUG TARGETING; FLUID RETENTION; FLUSHING; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY PERFUSION; NONHUMAN; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PLASMA HALF LIFE; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; REENTRY TACHYCARDIA; SIDE EFFECT; SINUS ARREST; SINUS NODE; SUPRAVENTRICULAR TACHYCARDIA;

ADENOSINE; ANIMALS; CARDIOVASCULAR DISEASES; CELL MEMBRANE; HUMANS; RECEPTORS, PURINERGIC P1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952794899     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029753     Document Type: Article

References (379)

1. Callow, A.D. Cardiovascular disease 2005-the global picture. Vas. Pharmacol., 2006, 45, 302-307. (Pubitemid 44765292)
2. Drury, A.N.; Szent-Gyorgyi, A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol., 1929, 68, 213-237.
3. Berne, R.M. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am. J. Physiol., 1963, 204, 317-322.
4. Burnstock, G. Purinergic receptors. J. Theor. Biol., 1976, 62, 491-503.
5. Kloner, R.A.; Forman, M.B.; Gibbons, R.J.; Ross, A.M.; Alexander, R.W.; Stone, G.W. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: The AMISTAD-2 trial. Eur. Heart J., 2006, 27, 2400-2405 (Pubitemid 44522145)
6. Desmet, W.J.; Dens, J.; Coussement, P.; Van de Werf, F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. ADEnosine Limit myocardial Necrosis. Heart, 2002, 88, 293-295. (Pubitemid 34913518)
7. Chaparro, S.; Dittrich, H.C.; Tang, W.W. Rolofylline (KW-3902): A new adenosine A1-receptor antagonist for acute congestive heart failure. Future Cardiol., 2008, 4, 117-123. (Pubitemid 351372594)
8. Givertz, M.M.; Massie, B.M.; Fields, T.K.; Pearson, L.L.; Dittrich, H.C. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol., 2007, 50, 1551-1560. (Pubitemid 47532320)
9. Niccoli, G.; D'Amario, D.; Spaziani, C.; Cosentino, N.; Marino, M.; Rigattieri, S.; Schiavo, P.L.; De Vita, M.R.; Tarantino, F.; Bartorelli, A.; Fabbiocchi, F.; Prati, F.; Imola, F.; Valgimigli, M.; Ferrari, R.; Crea, F. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: The REOPENAMI study protocol. J. Cardiovasc. Med. (Hagerstown), 2009, 10, 585-592.
10. Murray, J.J.; Weiler, J.M.; Schwartz, L.B.; Busse, W.W.; Katial, R.K.; Lockey, R.F.; McFadden, E.R., Jr.; Pixton, G.C.; Barrett, R.J. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma. Circ. Cardiovasc. Imaging, 2009, 2, 492-498.
11. Tejani, F.H.; Thompson, R.C.; Iskandrian, A.E.; McNutt, B.E.; Franks, B. Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: Rationale and design of a prospective, randomized, multicenter study. J. Nucl. Cardiol., 2010, DOI: 10.1007/s12350-010-9311-6.
12. Aljaroudi, W.; Iqbal, F.; Koneru, J.; Bhambhvani, P.; Heo, J.; Iskandrian, A.E. Safety of regadenoson in patients with end-stage liver disease. J. Nucl. Cardiol., 2010, DOI: 10.1007/s12350-010-9288-1.
13. Johnson, S.G.; Peters, S. Advances in pharmacologic stress agents: Focus on regadenoson. J. Nucl. Med. Technol., 2010, 38, 163-171.
14. Kwon, D.H.; Cerqueira, M.D.; Young, R.; Houghtaling, P.; Lieber, E.; Menon, V.; Brunken, R.C.; Jaber, W.A. Lessons from regadenoson and lowlevel treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients. J. Nucl. Cardiol., 2010, 17, 853-857.
15. Hage, F.G.; Perry, G.; Heo, J.; Iskandrian, A.E. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am. J. Cardiol., 2010, 105, 839-843.
16. Aljaroudi, W.; Hermann, D.; Hage, F.; Heo, J.; Iskandrian, A.E. Safety of regadenoson in patients with end-stage renal disease. Am. J. Cardiol., 2010, 105, 133-135.
17. Garnock-Jones, K.P.; Curran, M.P. Regadenoson. Am. J. Cardiovasc. Drugs, 2010, 10, 65-71.
18. Jagathesan, R.; Rosen, S.D.; Foale, R.A.; Camici, P.G.; Picano, E. Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: A substudy of the persantine in stable angina (PISA) study. J. Cardiovasc. Pharmacol., 2006, 48, 110-116. (Pubitemid 44562950)
19. Van Den Neste, E.; Van den Berghe, G.; Bontemps, F. AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies. Expert. Opin. Investig. Drugs, 2010, 19, 571-578.
20. Zhang, W.; Wang, J.; Wang, H.; Tang, R.; Belcher, J.D.; Viollet, B.; Geng, J.G.; Zhang, C.; Wu, C.; Slungaard, A.; Zhu, C.; Huo, Y. Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 1000-1006.
21. Robert, G.; Ben Sahra, I.; Puissant, A.; Colosetti, P.; Belhacene, N.; Gounon, P.; Hofman, P.; Bost, F.; Cassuto, J.P.; Auberger, P. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One, 2009, 4, e7889.
22. Drew, B.G.; Kingwell, B.A. Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin. Pharmacother., 2008, 9, 2137-2144.
23. Jacobson, K.A.; Gao, Z.G. Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov., 2006, 5, 247-264. (Pubitemid 43336037)
24. Moro, S.; Gao, Z.G.; Jacobson, K.A.; Spalluto, G. Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev., 2006, 26, 131-159. (Pubitemid 43334639)
25. Schenone, S.; Brullo, C.; Musumeci, F.; Bruno, O.; Botta, M. A1 receptors ligands: Past, present and future trends. Curr. Top. Med. Chem., 2010, 10, 878-901.
26. Baraldi, P.G.; Tabrizi, M.A.; Fruttarolo, F.; Romagnoli, R.; Preti, D. Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal., 2009, 5, 3-19.
27. Beukers, M.W.; Meurs, I.; Ijzerman, A.P. Structure-affinity relationships of adenosine A2B receptor ligands. Med. Res. Rev., 2006, 26, 667-698. (Pubitemid 44230416)
28. Muller, C.E. Medicinal chemistry of adenosine A3 receptor ligands. Curr. Top. Med. Chem., 2003, 3, 445-462.
29. Kalla, R.V.; Zablocki, J.; Tabrizi, M.A.; Baraldi, P.G. Recent developments in A2B adenosine receptor ligands. Handb. Exp. Pharmacol., 2009, 99-122.
30. Cristalli, G.; Muller, C.E.; Volpini, R. Recent developments in adenosine A2A receptor ligands. Handb. Exp. Pharmacol., 2009, 59-98.
31. Baraldi, P.G.; Tabrizi, M.A.; Gessi, S.; Borea, P.A. Adenosine receptor antagonists: Translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev., 2008, 108, 238-263. (Pubitemid 351176408)
32. Givertz, M.M. Adenosine A1 receptor antagonists at a fork in the road. Circ. Heart Fail., 2009, 2, 519-522.
33. Clementina, M.; Giuseppe, S. A2A receptor ligands: Past, present and future trends. Curr. Top Med. Chem., 2010, 10, 902-922.
34. Burnstock, G. Purinergic receptors in the heart. Circ. Res., 1980, 46, I175- 182. (Pubitemid 11205564)
35. Fredholm, B.B.; Ap, I.J.; Jacobson, K.A.; Klotz, K.N.; Linden, J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., 2001, 53, 527-552. (Pubitemid 33136237)
36. Jacobson, K.A.; van Galen, P.J.; Williams, M. Adenosine receptors: Pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem., 1992, 35, 407-422.
37. Palmer, T.M.; Stiles, G.L. Adenosine receptors. Neuropharmacology, 1995, 34, 683-694.
38. Olah, M.E.; Stiles, G.L. Adenosine receptor subtypes: Characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 581-606.
39. Poulsen, S.A.; Quinn, R.J. Adenosine receptors: New opportunities for future drugs. Bioorg. Med. Chem., 1998, 6, 619-641. (Pubitemid 28287266)
40. Stiles, G.L. Adenosine receptors. J. Biol. Chem., 1992, 267, 6451-6454.
41. Shryock, J.C.; Belardinelli, L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. Am. J. Cardiol., 1997, 79, 2-10. (Pubitemid 27305162)
42. Deckert, J.; Nothen, M.M.; Bryant, S.P.; Ren, H.; Wolf, H.K.; Stiles, G.L.; Spurr, N.K.; Propping, P. Human adenosine A1 receptor gene: Systematic screening for DNA sequence variation and linkage mapping on chromosome 1q31-32.1 using a silent polymorphism in the coding region. Biochem. Biophys. Res. Commun., 1995, 214, 614-621.
43. Klotz, K.N. Adenosine receptors and their ligands. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 362, 382-391.
44. Klinger, M.; Freissmuth, M.; Nanoff, C. Adenosine receptors: G proteinmediated signalling and the role of accessory proteins. Cell. Signal., 2002, 14, 99-108. (Pubitemid 34056581)
45. Lee, J.E.; Bokoch, G.; Liang, B.T. A novel cardioprotective role of RhoA: New signaling mechanism for adenosine. FASEB J., 2001, 15, 1886-1894. (Pubitemid 32848792)
46. Henry, P.; Demolombe, S.; Puceat, M.; Escande, D. Adenosine A1 stimulation activates delta-protein kinase C in rat ventricular myocytes. Circ. Res., 1996, 78, 161-165.
47. Hu, K.; Duan, D.; Li, G.R.; Nattel, S. Protein kinase C activates ATPsensitive K+ current in human and rabbit ventricular myocytes. Circ. Res., 1996, 78, 492-498.
48. Bohm, M.; Bruckner, R.; Hackbarth, I.; Haubitz, B.; Linhart, R.; Meyer, W.; Schmidt, B.; Schmitz, W.; Scholz, H. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect. J. Pharmacol. Exp. Ther., 1984, 230, 483-492.
49. Belardinelli, L.; Shryock, J.C.; Song, Y.; Wang, D.; Srinivas, M. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J., 1995, 9, 359-365.
50. Auchampach, J.A.; Gross, G.J. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs. Am. J. Physiol., 1993, 264, H1327- 1336. (Pubitemid 23154115)
51. Shimoni, Y.; Han, X.; Severson, D.; Giles, W.R. Mediation by nitric oxide of the indirect effects of adenosine on calcium current in rabbit heart pacemaker cells. Br. J. Pharmacol., 1996, 119, 1463-1469. (Pubitemid 26402025)
52. Martynyuk, A.E.; Kane, K.A.; Cobbe, S.M.; Rankin, A.C. Nitric oxide mediates the anti-adrenergic effect of adenosine on calcium current in isolated rabbit atrioventricular nodal cells. Pflugers Arch., 1996, 431, 452-457. (Pubitemid 26083008)
53. Fredholm, B.B.; Chern, Y.; Franco, R.; Sitkovsky, M. Aspects of the general biology of adenosine A2A signaling. Prog. Neurobiol., 2007, 83, 263-276. (Pubitemid 350102746)
54. Palmer, T.M.; Gettys, T.W.; Jacobson, K.A.; Stiles, G.L. Desensitization of the canine A2a adenosine receptor: Delineation of multiple processes. Mol. Pharmacol., 1994, 45, 1082-1094.
55. Deckert, J.; Nothen, M.M.; Rietschel, M.; Wildenauer, D.; Bondy, B.; Ertl, M.A.; Knapp, M.; Schofield, P.R.; Albus, M.; Maier, W.; Propping, P. Human adenosine A2a receptor (A2aAR) gene: Systematic mutation screening in patients with schizophrenia. J. Neural. Transm., 1996, 103, 1447-1455.
56. Le, F.; Townsend-Nicholson, A.; Baker, E.; Sutherland, G.R.; Schofield, P.R. Characterization and chromosomal localization of the human A2a adenosine receptor gene: ADORA2A. Biochem. Biophys. Res. Commun., 1996, 223, 461-467. (Pubitemid 26245590)
57. Soma, M.; Nakayama, T.; Satoh, M.; Uwabo, J.; Rahmutula, D.; Takahashi, Y.; Fukuda, N.; Watanabe, Y.; Izumi, Y.; Kanmatsuse, K. A T1083C polymorphism in the human adenosine A2a receptor gene is not associated with essential hypertension. Am. J. Hypertens., 1998, 11, 1492-1494. (Pubitemid 29030316)
58. Kull, B.; Svenningsson, P.; Fredholm, B.B. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Mol. Pharmacol., 2000, 58, 771-777.
59. Ciruela, F.; Albergaria, C.; Soriano, A.; Cuffi, L.; Carbonell, L.; Sanchez, S.; Gandia, J.; Fernandez-Duenas, V. Adenosine receptors interacting proteins (ARIPs): Behind the biology of adenosine signaling. Biochim. Biophys. Acta, 2010, 1798, 9-20.
60. Daly, J.W.; Butts-Lamb, P.; Padgett, W. Subclasses of adenosine receptors in the central nervous system: Interaction with caffeine and related methylxanthines. Cell Mol. Neurobiol., 1983, 3, 69-80. (Pubitemid 13014444)
61. Bruns, R.F.; Lu, G.H.; Pugsley, T.A. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol. Pharmacol., 1986, 29, 331-346. (Pubitemid 16078480)
62. Marquardt, D.L.; Walker, L.L.; Heinemann, S. Cloning of two adenosine receptor subtypes from mouse bone marrow-derived mast cells. J. Immunol., 1994, 152, 4508-4515. (Pubitemid 24134408)
63. Stehle, J.H.; Rivkees, S.A.; Lee, J.J.; Weaver, D.R.; Deeds, J.D.; Reppert, S.M. Molecular cloning and expression of the cDNA for a novel A2- adenosine receptor subtype. Mol. Endocrinol., 1992, 6, 384-393.
64. Rivkees, S.A.; Reppert, S.M. RFL9 encodes an A2b-adenosine receptor. Mol. Endocrinol., 1992, 6, 1598-1604.
65. Pierce, K.D.; Furlong, T.J.; Selbie, L.A.; Shine, J. Molecular cloning and expression of an adenosine A2b receptor from human brain. Biochem. Biophys. Res. Commun., 1992, 187, 86-93.
66. Varani, K.; Gessi, S.; Merighi, S.; Vincenzi, F.; Cattabriga, E.; Benini, A.; Klotz, K.N.; Baraldi, P.G.; Tabrizi, M.A.; Lennan, S.M.; Leung, E.; Borea, P.A. Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem. Pharmacol., 2005, 70, 1601-1612. (Pubitemid 41540353)
67. Ji, X.; Kim, Y.C.; Ahern, D.G.; Linden, J.; Jacobson, K.A. [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem. Pharmacol., 2001, 61, 657-663. (Pubitemid 32239418)
68. Auchampach, J.A.; Kreckler, L.M.; Wan, T.C.; Maas, J.E.; van der Hoeven, D.; Gizewski, E.; Narayanan, J.; Maas, G.E. Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. J. Pharmacol. Exp. Ther., 2009, 329, 2-13.
69. Salvatore, C.A.; Jacobson, M.A.; Taylor, H.E.; Linden, J.; Johnson, R.G. Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA, 1993, 90, 10365-10369. (Pubitemid 23328313)
70. Linden, J.; Taylor, H.E.; Robeva, A.S.; Tucker, A.L.; Stehle, J.H.; Rivkees, S.A.; Fink, J.S.; Reppert, S.M. Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution. Mol. Pharmacol., 1993, 44, 524-532. (Pubitemid 23280262)
71. Zhou, Q.Y.; Li, C.; Olah, M.E.; Johnson, R.A.; Stiles, G.L.; Civelli, O. Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc. Natl. Acad. Sci. USA, 1992, 89, 7432-7436.
72. Murrison, E.M.; Goodson, S.J.; Edbrooke, M.R.; Harris, C.A. Cloning and characterisation of the human adenosine A3 receptor gene. FEBS Lett., 1996, 384, 243-246. (Pubitemid 26125230)
73. Parsons, M.; Young, L.; Lee, J.E.; Jacobson, K.A.; Liang, B.T. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D. FASEB J., 2000, 14, 1423-1431. (Pubitemid 30439751)
74. Trincavelli, M.L.; Tuscano, D.; Marroni, M.; Falleni, A.; Gremigni, V.; Ceruti, S.; Abbracchio, M.P.; Jacobson, K.A.; Cattabeni, F.; Martini, C. A3 adenosine receptors in human astrocytoma cells: Agonist-mediated desensitization, internalization, and down-regulation. Mol. Pharmacol., 2002, 62, 1373-1384. (Pubitemid 35403832)
75. Belardinelli, L.; Linden, J.; Berne, R.M. The cardiac effects of adenosine. Prog. Cardiovasc. Dis., 1989, 32, 73-97. (Pubitemid 19175413)
76. Lerman, B.B.; Belardinelli, L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation, 1991, 83, 1499-1509.
77. Vinten-Johansen, J.; Thourani, V.H.; Ronson, R.S.; Jordan, J.E.; Zhao, Z.Q.; Nakamura, M.; Velez, D.; Guyton, R.A. Broad-spectrum cardioprotection with adenosine. Ann. Thorac. Surg., 1999, 68, 1942-1948.
78. Szentmiklosi, A.J.; Nemeth, M.; Cseppento, A.; Szegi, J.; Papp, J.G.; Szekeres, L. Effects of hypoxia on the guinea-pig myocardium following inhibition of adenosine deaminase by coformycin. Arch. Int. Pharmacodyn. Ther., 1984, 269, 287-294. (Pubitemid 14116809)
79. Szentmiklosi, A.J.; Nemeth, M.; Szegi, J.; Papp, J.G.; Szekeres, L. On the possible role of adenosine in the hypoxia-induced alterations of the electrical and mechanical activity of the atrial myocardium. Arch. Int. Pharmacodyn. Ther., 1979, 238, 283-295. (Pubitemid 9180866)
80. Clark, A.N.; Youkey, R.; Liu, X.; Jia, L.; Blatt, R.; Day, Y.J.; Sullivan, G.W.; Linden, J.; Tucker, A.L. A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ. Res., 2007, 101, 1130-1138. (Pubitemid 350146439)
81. Olsson, R.A.; Pearson, J.D. Cardiovascular purinoceptors. Physiol. Rev., 1990, 70, 761-845. (Pubitemid 20196050)
82. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev., 1998, 50, 413-492. (Pubitemid 28477681)
83. Berne, R.M. The role of adenosine in the regulation of coronary blood flow. Circ. Res., 1980, 47, 807-813. (Pubitemid 11217044)
84. Versprille, A. The chronotropic effect of adenine- and hypoxanthine derivatives on isolated rat hearts before and after removing the sino-auricular node. Pflugers Arch. Gesamte Physiol. Menschen Tiere, 1966, 291, 261-267.
85. DiMarco, J.P.; Sellers, T.D.; Berne, R.M.; West, G.A.; Belardinelli, L. Adenosine: Electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation, 1983, 68, 1254-1263. (Pubitemid 14207037)
86. Szentmiklosi, A.J.; Nemeth, M.; Szegi, J.; Papp, J.G.; Szekeres, L. Effect of adenosine on sinoatrial and ventricular automaticity of the guinea pig. Naunyn Schmiedebergs Arch. Pharmacol., 1980, 311, 147-149. (Pubitemid 10156679)
87. James, T.N. The chronotropic action of ATP and related compounds studied by direct perfusion of the sinus node. J. Pharmacol. Exp. Ther., 1965, 149, 233-247.
88. Chiba, S.; Hashimoto, K. Differences in chronotropic and dromotropic responses of the SA and AV nodes to adenosine and acetylcholine. Jpn. J. Pharmacol., 1972, 22, 273-274.
89. Urthaler, F.; James, T.N. Effects of adenosine and ATP on AV conduction and on AV junctional rhythm. J. Lab. Clin. Med., 1972, 79, 96-105.
90. Pelleg, A.; Hurt, C.; Miyagawa, A.; Michelson, E.L.; Dreifus, L.S. Differential sensitivity of cardiac pacemakers to exogenous adenosine in vivo. Am. J. Physiol., 1990, 258, H1815-1822. (Pubitemid 20226317)
91. Belardinelli, L.; Isenberg, G. Isolated atrial myocytes: Adenosine and acetylcholine increase potassium conductance. Am. J. Physiol., 1983, 244, H734-737. (Pubitemid 13088957)
92. West, G.A.; Belardinelli, L. Correlation of sinus slowing and hyperpolarization caused by adenosine in sinus node. Pflugers Arch., 1985, 403, 75-81. (Pubitemid 15161295)
93. West, G.A.; Belardinelli, L. Sinus slowing and pacemaker shift caused by adenosine in rabbit SA node. Pflugers Arch., 1985, 403, 66-74. (Pubitemid 15161294)
94. Wang, D.; Belardinelli, L. Mechanism of the negative inotropic effect of adenosine in guinea pig atrial myocytes. Am. J. Physiol., 1994, 267, H2420- 2429.
95. Pelleg, A.; Belardinelli, L. Cardiac electrophysiology and pharmacology of adenosine: Basic and clinical aspects. Cardiovasc. Res., 1993, 27, 54-61. (Pubitemid 23035666)
96. Honey, R.M.R.,; Thomson, W.A.R. The action of adenosine upon the human heart. Q. J. Med., 1930, 23, 485-490.
97. Watt, A.H.; Bayer, A.; Routledge, P.A.; Swift, C.G. Adenosine-induced respiratory and heart rate changes in young and elderly adults. Br. J. Clin. Pharmacol., 1989, 27, 265-267. (Pubitemid 19059491)
98. Watt, A.H.; Routledge, P.A. Transient bradycardia and subsequent sinus tachycardia produced by intravenous adenosine in healthy adult subjects. Br. J. Clin. Pharmacol., 1986, 21, 533-536. (Pubitemid 17175028)
99. Watt, A.H. Sick sinus syndrome and adenosine. Lancet, 1985, 1, 1340. (Pubitemid 15059179)
100. Watt, A.H. Sick sinus syndrome: An adenosine-mediated disease. Lancet, 1985, 1, 786-788. (Pubitemid 15103882)
101. Wilbur, S.L.; Marchlinski, F.E. Adenosine as an antiarrhythmic agent. Am. J. Cardiol., 1997, 79, 30-37. (Pubitemid 27305166)
102. Lerman, B.B.; Wesley, R.C., Jr.; DiMarco, J.P.; Haines, D.E.; Belardinelli, L. Antiadrenergic effects of adenosine on His-Purkinje automaticity. Evidence for accentuated antagonism. J. Clin. Invest., 1988, 82, 2127-2135. (Pubitemid 19054962)
103. Levy, M.N. Sympathetic-parasympathetic interactions in the heart. Circ. Res., 1971, 29, 437-445.
104. Levy, M.N. Cardiac sympathetic-parasympathetic interactions. Fed. Proc., 1984, 43, 2598-2602. (Pubitemid 14055997)
105. Lerman, B.B.; Belardinelli, L.; West, G.A.; Berne, R.M.; DiMarco, J.P. Adenosine-sensitive ventricular tachycardia: Evidence suggesting cyclic AMP-mediated triggered activity. Circulation, 1986, 74, 270-280. (Pubitemid 16072122)
106. Lokhandwala, M.F. Inhibition of cardiac sympathetic neurotransmission by adenosine. Eur. J. Pharmacol., 1979, 60, 353-357. (Pubitemid 10168947)
107. Bohm, M.; Bruckner, R.; Meyer, W.; Nose, M.; Schmitz, W.; Scholz, H.; Starbatty, J. Evidence for adenosine receptor-mediated isoprenalineantagonistic effects of the adenosine analogs PIA and NECA on force of contraction in guinea-pig atrial and ventricular cardiac preparations. Naunyn Schmiedebergs Arch. Pharmacol., 1985, 331, 131-139. (Pubitemid 16211031)
108. Belardinelli, L.; Vogel, S.; Linden, J.; Berne, R.M. Antiadrenergic action of adenosine on ventricular myocardium in embryonic chick hearts. J. Mol. Cell. Cardiol., 1982, 14, 291-294. (Pubitemid 12039032)
109. Stafford, A. Potentiation of adenosine and the adenine nucleotides by dipyridamole. Br. J. Pharmacol. Chemother., 1966, 28, 218-227.
110. Toft, J.; Mortensen, J.; Hesse, B. Risk of atrioventricular block during adenosine pharmacologic stress testing in heart transplant recipients. Am. J. Cardiol., 1998, 82, 696-697, A699.
111. Harvey, M.G.; Safih, S.; Wallace, M. Adenosine-induced complete heart block: Not so transient. Emerg. Med. Australas., 2007, 19, 559-562. (Pubitemid 350132666)
112. Clemo, H.F.; Belardinelli, L. Effect of adenosine on atrioventricular conduction. II: Modulation of atrioventricular node transmission by adenosine in hypoxic isolated guinea pig hearts. Circ. Res., 1986, 59, 437-446. (Pubitemid 17211723)
113. Rotmensch, H.H.; Rotmensch, S.; Elkayam, U. Management of cardiac arrhythmias during pregnancy. Current concepts. Drugs, 1987, 33, 623-633. (Pubitemid 17077732)
114. Clarke, B.; Till, J.; Rowland, E.; Ward, D.E.; Barnes, P.J.; Shinebourne, E.A. Rapid and safe termination of supraventricular tachycardia in children by adenosine. Lancet, 1987, 1, 299-301. (Pubitemid 17009791)
115. Till, J.; Shinebourne, E.A.; Rigby, M.L.; Clarke, B.; Ward, D.E.; Rowland, E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br. Heart J., 1989, 62, 204-211. (Pubitemid 19217075)
116. Rossi, A.F.; Steinberg, L.G.; Kipel, G.; Golinko, R.J.; Griepp, R.B. Use of adenosine in the management of perioperative arrhythmias in the pediatric cardiac intensive care unit. Crit. Care Med., 1992, 20, 1107-1111.
117. Overholt, E.D.; Rheuban, K.S.; Gutgesell, H.P.; Lerman, B.B.; DiMarco, J.P. Usefulness of adenosine for arrhythmias in infants and children. Am. J. Cardiol., 1988, 61, 336-340
118. Klabunde, R.E. Dipyridamole inhibition of adenosine metabolism in human blood. Eur. J. Pharmacol., 1983, 93, 21-26. (Pubitemid 13005927)
119. Ontyd, J.; Schrader, J. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J. Chromatogr., 1984, 307, 404-409. (Pubitemid 14102635)
120. Moser, G.H.; Schrader, J.; Deussen, A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol., 1989, 256, C799-806.
121. Rankin, A.C.; Rae, A.P.; Oldroyd, K.G.; Cobbe, S.M. Verapamil or adenosine for the immediate treatment of supraventricular tachycardia. Q. J. Med., 1990, 74, 203-208. (Pubitemid 20059791)
122. Rosales, O.R.; Eades, B.; Assali, A.R. Cardiovascular drugs: Adenosine role in coronary syndromes and percutaneous coronary interventions. Catheter. Cardiovasc. Interv., 2004, 62, 358-363. (Pubitemid 38868875)
123. Auchampach, J.A.; Bolli, R. Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges. Am. J. Physiol., 1999, 276, H1113- 1116. (Pubitemid 29157489)
124. Norton, G.R.; Woodiwiss, A.J.; McGinn, R.J.; Lorbar, M.; Chung, E.S.; Honeyman, T.W.; Fenton, R.A.; Dobson, J.G., Jr.; Meyer, T.E. Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart. Am. J. Physiol., 1999, 276, H341-349. (Pubitemid 29100599)
125. Conti, J.B.; Belardinelli, L.; Curtis, A.B. Usefulness of adenosine in diagnosis of tachyarrhythmias. Am. J. Cardiol., 1995, 75, 952-955.
126. Mallet, M.L. Proarrhythmic effects of adenosine: A review of the literature. Emerg. Med. J., 2004, 21, 408-410. (Pubitemid 38967449)
127. Pelleg, A.; Pennock, R.S.; Kutalek, S.P. Proarrhythmic effects of adenosine: One decade of clinical data. Am. J. Ther., 2002, 9, 141-147.
128. Tomcsanyi, J.; Tenczer, J.; Horvath, L. Unusual effect of adenosine. Int. J. Cardiol., 1995, 49, 89-91.
129. Brodsky, M.A.; Hwang, C.; Hunter, D.; Chen, P.S.; Smith, D.; Ariani, M.; Johnston, W.D.; Allen, B.J.; Chun, J.G.; Gold, C.R. Life-threatening alterations in heart rate after the use of adenosine in atrial flutter. Am. Heart J., 1995, 130, 564-571.
130. McCollam, P.L.; Uber, W.E.; Van Bakel, A.B. Adenosine-related ventricular asystole. Ann. Intern. Med., 1993, 118, 315-316.
131. Misra, D.; Van Tosh, A.; Schweitzer, P. Adenosine induced monomorphic ventricular tachycardia. Pacing Clin. Electrophysiol., 2000, 23, 1044-1046. (Pubitemid 30413615)
132. DiMarco, J.P.; Miles, W.; Akhtar, M.; Milstein, S.; Sharma, A.D.; Platia, E.; McGovern, B.; Scheinman, M.M.; Govier, W.C. Adenosine for paroxysmal supraventricular tachycardia: Dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann. Intern. Med., 1990, 113, 104-110. (Pubitemid 20218627)
133. diMarco, J.P.; Sellers, T.D.; Lerman, B.B.; Greenberg, M.L.; Berne, R.M.; Belardinelli, L. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J. Am. Coll. Cardiol., 1985, 6, 417-425. (Pubitemid 15048821)
134. Munoz, A.; Leenhardt, A.; Sassine, A.; Galley, P.; Puech, P. Therapeutic use of adenosine for terminating spontaneous paroxysmal supraventricular tachycardia. Eur. Heart J., 1984, 5, 735-738. (Pubitemid 14006306)
135. Bertolet, B.D.; Hill, J.A.; Kerensky, R.A.; Belardinelli, L. Myocardial infarction related atrial fibrillation: Role of endogenous adenosine. Heart, 1997, 78, 88-90. (Pubitemid 27346888)
136. Bertolet, B.D.; Eagle, D.A.; Conti, J.B.; Mills, R.M.; Belardinelli, L. Bradycardia after heart transplantation: Reversal with theophylline. J. Am. Coll. Cardiol., 1996, 28, 396-399. (Pubitemid 26274334)
137. Kaiser, S.M.; Quinn, R.J. Adenosine receptors as potential therapeutic targets. Drug Discov. Today, 1999, 4, 542-551. (Pubitemid 29525379)
138. Engelstein, E.D.; Lippman, N.; Stein, K.M.; Lerman, B.B. Mechanismspecific effects of adenosine on atrial tachycardia. Circulation, 1994, 89, 2645-2654. (Pubitemid 24173683)
139. Garratt, C.; Antoniou, A.; Ward, D.; Camm, A.J. Misuse of verapamil in preexcited atrial fibrillation. Lancet, 1989, 1, 367-369. (Pubitemid 19103083)
140. Camm, A.J.; Garratt, C.J. Adenosine and supraventricular tachycardia. N. Engl. J. Med., 1991, 325, 1621-1629.
141. Epstein, M.L.; Belardinelli, L. Failure of adenosine to terminate focal atrial tachycardia. Pediatr. Cardiol., 1993, 14, 119-121. (Pubitemid 23108273)
142. Perelman, M.S.; Krikler, D.M. Termination of focal atrial tachycardia by adenosine triphosphate. Br. Heart J., 1987, 58, 528-530. (Pubitemid 17162475)
143. Camaiti, A.; Pieralli, F.; Olivotto, I.; Grifoni, S.; Conti, A.; Del Rosso, A.; Berni, G. Prospective evaluation of adenosine-induced proarrhythmia in the emergency room. Eur. J. Emerg. Med., 2001, 8, 99-105.
144. Prystowsky, E.N.; Benson, D.W., Jr.; Fuster, V.; Hart, R.G.; Kay, G.N.; Myerburg, R.J.; Naccarelli, G.V.; Wyse, D.G. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation, 1996, 93, 1262-1277.
145. Slade, A.K.; Garratt, C.J. Proarrhythmic effect of adenosine in a patient with atrial flutter. Br. Heart J., 1993, 70, 91-92. (Pubitemid 23243753)
146. Bertolet, B.D.; Hill, J.A. Adenosine: Diagnostic and therapeutic uses in cardiovascular medicine. Chest, 1993, 104, 1860-1871. (Pubitemid 23360123)
147. Rankin, A.C.; Oldroyd, K.G.; Chong, E.; Rae, A.P.; Cobbe, S.M. Value and limitations of adenosine in the diagnosis and treatment of narrow and broad complex tachycardias. Br. Heart J., 1989, 62, 195-203. (Pubitemid 19217074)
148. Garratt, C.; Ward, D.; Camm, A.J. Degeneration of junctional tachycardia to pre-excited atrial fibrillation after intravenous verapamil. Lancet, 1989, 2, 219. (Pubitemid 19187016)
149. Hollander, P.B.; Webb, J.L. Effects of adenine nucleotides on the contractility and membrane potentials of rat atrium. Circ. Res., 1957, 5, 349-353.
150. Grossman, A.; Furchgott, R.F. The effects of various drugs on calcium exchange in the isolated guinea-pig left auricle. J. Pharmacol. Exp. Ther., 1964, 145, 162-172.
151. Degubareff, T.; Sleator, W., Jr. Effects of caffeine on mammalian atrial muscle, and its interaction with adenosine and calcium. J. Pharmacol. Exp. Ther., 1965, 148, 202-214.
152. Bohm, M.; Meyer, W.; Mugge, A.; Schmitz, W.; Scholz, H. Functional evidence for the existence of adenosine receptors in the human heart. Eur. J. Pharmacol., 1985, 116, 323-326. (Pubitemid 16191825)
153. Collis, M.G. Evidence for an A1-adenosine receptor in the guinea-pig atrium. Br. J. Pharmacol., 1983, 78, 207-212. (Pubitemid 13167597)
154. Szentmiklosi, A.J.; Nemeth, M.; Cseppento, A.; Szegi, J.; Papp, J.G.; Szekeres, L. Potentiation of the myocardial actions of adenosine in the presence of coformycin, a specific inhibitor of adenosine deaminase. Arch. Int. Pharmacodyn. Ther., 1982, 256, 236-252. (Pubitemid 12136226)
155. Jochem, G.; Nawrath, H. Adenosine activates a potassium conductance in guinea-pig atrial heart muscle. Experientia, 1983, 39, 1347-1349. (Pubitemid 14203731)
156. Schrader, J.; Rubio, R.; Berne, R.M. Inhibition of slow action potentials of guinea pig atrial muscle by adenosine: A possible effect on Ca2+ influx. J. Mol. Cell. Cardiol., 1975, 7, 427-433.
157. Fassina, G.; de Biasi, M.; Ragazzi, E.; Caparrotta, L. Adenosine: A natural modulator of L-type calcium channels in atrial myocardium? Pharmacol. Res., 1991, 23, 319-326.
158. Bohm, M.; Burmann, H.; Meyer, W.; Nose, M.; Schmitz, W.; Scholz, H. Positive inotropic effect of Bay K 8644: CAMP-independence and lack of inhibitory effect of adenosine. Naunyn Schmiedebergs Arch. Pharmacol., 1985, 329, 447-450. (Pubitemid 15021301)
159. Bruckner, R.; Fenner, A.; Meyer, W.; Nobis, T.M.; Schmitz, W.; Scholz, H. Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: Evidence against a role of cyclic AMP and cyclic GMP. J. Pharmacol. Exp. Ther., 1985, 234, 766-774. (Pubitemid 15240561)
160. Buckley, N.M. Cardiac effects of nucleosides after propranolol treatment of isolated hearts. Am. J. Physiol., 1970, 218, 1399-1405.
161. Chiba, S.; Himori, N. Different inotropic responses to adenosine on the atrial and ventricular muscle of the dog heart. Jpn. J. Pharmacol., 1975, 25, 489-491.
162. Schrader, J.; Baumann, G.; Gerlach, E. Adenosine as inhibitor of myocardial effects of catecholamines. Pflugers Arch., 1977, 372, 29-35. (Pubitemid 8226016)
163. Dobson, J.G., Jr. Mechanism of adenosine inhibition of catecholamineinduced responses in heart. Circ. Res., 1983, 52, 151-160. (Pubitemid 13142015)
164. Isenberg, G.; Belardinelli, L. Ionic basis for the antagonism between adenosine and isoproterenol on isolated mammalian ventricular myocytes. Circ.
165. Dobson, J.G., Jr. Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle. Circ. Res., 1978, 43, 785-792. (Pubitemid 9054872)
166. Endoh, M.; Yamashita, S. Adenosine antagonizes the positive inotropic action mediated via beta-, but not alpha-adrenoceptors in the rabbit papillary muscle. Eur. J. Pharmacol., 1980, 65, 445-448. (Pubitemid 10034686)
167. Hughes, P.R.; Stone, T.W. Inhibition by purines of the inotropic action of isoprenaline in rat atria. Br. J. Pharmacol., 1983, 80, 149-153. (Pubitemid 13000890)
168. Merkel, L.A.; Lappe, R.W.; Rivera, L.M.; Cox, B.F.; Perrone, M.H. Demonstration of vasorelaxant activity with an A1-selective adenosine agonist in porcine coronary artery: Involvement of potassium channels. J. Pharmacol. Exp. Ther., 1992, 260, 437-443.
169. Hedqvist, P.; Fredholm, B.B. Effects of adenosine on adrenergic neurotransmission; prejunctional inhibition and postjunctional enhancement. Naunyn Schmiedebergs Arch. Pharmacol., 1976, 293, 217-223.
170. Brown, C.M.; Collis, M.G. Adenosine A1 receptor mediated inhibition of nerve stimulation-induced contractions of the rabbit portal vein. Eur. J. Pharmacol., 1983, 93, 277-282. (Pubitemid 13009703)
171. Schnaar, R.L.; Sparks, H.V. Response of large and small coronary arteries to nitroglycerin, NaNO 2 , and adenosine. Am. J. Physiol., 1972, 223, 223-228.
172. Willems, L.; Ashton, K.J.; Headrick, J.P. Adenosine-mediated cardioprotection in the aging myocardium. Cardiovasc. Res., 2005, 66, 245-255. (Pubitemid 40471039)
173. Mubagwa, K.; Flameng, W. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovasc. Res., 2001, 52, 25-39. (Pubitemid 32835236)
174. Berne, R.M. Adenosine-a cardioprotective and therapeutic agent. Cardiovasc. Res., 1993, 27, 2. (Pubitemid 23035658)
175. Forman, M.B.; Velasco, C.E.; Jackson, E.K. Adenosine attenuates reperfusion injury following regional myocardial ischaemia. Cardiovasc. Res., 1993, 27, 9-17. (Pubitemid 23035660)
176. Sommerschild, H.T.; Kirkeboen, K.A. Adenosine and cardioprotection during ischaemia and reperfusion-an overview. Acta Anaesthesiol. Scand., 2000, 44, 1038-1055.
177. Juhasz-Nagy, A.; Papp, L. Are coronary vasodilator effects of inosine and adenosine independent of each other? J. Cardiovasc. Pharmacol., 1982, 4, 330-331. (Pubitemid 12133417)
178. Kekesi, V.; Zima, E.; Barat, E.; Huszar, E.; Nagy, A.; Losonczi, L.; Merkely, B.; Horkay, F.; Juhasz-Nagy, A. Pericardial concentrations of adenosine, inosine and hypoxanthine in an experimental canine model of spastic ischaemia. Clin. Sci. (Lond.), 2002, 103 Suppl. 48, 198S-201S. (Pubitemid 35007151)
179. Howarth, S.; Mc, M.J.; Sharpey-Schafer, E.P. The circulatory action of theophylline ethylene diamine. Clin. Sci. (Lond.), 1947, 6, 125-135.
180. Parker, J.O.; Kelly, G.; West, R.O. Hemodynamic effects of aminophylline in heart failure. Am. J. Cardiol., 1966, 17, 232-239.
181. Murphy, G.W.; Schreiner, B.F., Jr.; Yu, P.N. Effects of aminophylline on the pulmonary circulation and left ventricular performance in patients with valvular heart disease. Circulation, 1968, 37, 361-369.
182. Al-Damluji, S.; Nathan, A.W.; Johnston, A.; Banim, S.O.; Spurrell, R.A.; Camm, A.J. Oral theophylline in chronic heart failure. Postgrad. Med. J., 1982, 58, 216-221. (Pubitemid 12100325)
183. Scholz, H. [Mechanism of the positive ionotropic action of theophylline on the mammalian heart. 3. Effect of theophylline on contraction and Ca dependent changes in membrane potentials]. Naunyn Schmiedebergs Arch. Pharmacol., 1971, 271, 410-429.
184. Scholz, H. [Mechanism of the positive ionotropic action of theophylline on the mammalian heart. 2. Effect of theophylline on the uptake and release of 45 Ca]. Naunyn Schmiedebergs Arch. Pharmacol., 1971, 271, 396-409.
185. Scholz, H.; de Yazikof, E. [Mechanism of the positive ionotropic action of theophylline on the mamalian heart. I. Influence of extracellular Ca, Na and K concentrations and of reserpine]. Naunyn Schmiedebergs Arch. Pharmacol., 1971, 271, 374-395.
186. Skelton, C.L.; Levey, G.S.; Epstein, S.E. Positive inotropic effects of dibutyryl cyclic adenosine 3',5'-monophosphate. Circ. Res., 1970, 26, 35-43.
187. Rang, H.; Dale, M. Rang and Dale's Pharmacology. 6th ed.; Churchill Livingstone, 2007; p. 362.
188. Rabe, K.F.; Magnussen, H.; Dent, G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J., 1995, 8, 637-642.
189. Asakura, M.; Asanuma, H.; Kim, J.; Liao, Y.; Nakamaru, K.; Fujita, M.; Komamura, K.; Isomura, T.; Furukawa, H.; Tomoike, H.; Kitakaze, M. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. Hypertens. Res., 2007, 30, 781-787. (Pubitemid 47578239)
190. Gottlieb, S.S. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs, 2001, 61, 1387-1393. (Pubitemid 32783742)
191. Funaya, H.; Kitakaze, M.; Node, K.; Minamino, T.; Komamura, K.; Hori, M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation, 1997, 95, 1363-1365. (Pubitemid 27142790)
192. Elkayam, U.; Mehra, A.; Cohen, G.; Tummala, P.P.; Karaalp, I.S.; Wani, O.R.; Canetti, M. Renal circulatory effects of adenosine in patients with chronic heart failure. J. Am. Coll. Cardiol., 1998, 32, 211-215. (Pubitemid 28351064)
193. Lucas, D.G., Jr.; Hendrick, J.W.; Sample, J.A.; Mukherjee, R.; Escobar, G.P.; Smits, G.J.; Crawford, F.A., Jr.; Spinale, F.G. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J. Am. Coll. Surg., 2002, 194, 603-609. (Pubitemid 34496655)
194. Gottlieb, S.S.; Robinson, S.; Weir, M.R.; Fisher, M.L.; Krichten, C.M. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am. Heart J., 1992, 124, 131-136.
195. Gottlieb, S.S.; Robinson, S.; Krichten, C.M.; Fisher, M.L. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol., 1992, 70, 890-893.
196. Tenstad, O.; Williamson, H.E. Effect of furosemide on local and zonal glomerular filtration rate in the rat kidney. Acta Physiol. Scand., 1995, 155, 99-107.
197. Gottlieb, S.S.; Skettino, S.L.; Wolff, A.; Beckman, E.; Fisher, M.L.; Freudenberger, R.; Gladwell, T.; Marshall, J.; Cines, M.; Bennett, D.; Liittschwager, E.B. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J. Am. Coll. Cardiol., 2000, 35, 56-59. (Pubitemid 30061259)
198. Gottlieb, S.S.; Brater, D.C.; Thomas, I.; Havranek, E.; Bourge, R.; Goldman, S.; Dyer, F.; Gomez, M.; Bennett, D.; Ticho, B.; Beckman, E.; Abraham, W.T. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation, 2002, 105, 1348-1353. (Pubitemid 34260427)
199. Cotter, G.; Dittrich, H.C.; Weatherley, B.D.; Bloomfield, D.M.; O'Connor, C.M.; Metra, M.; Massie, B.M. The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J. Cardiol. Fail., 2008, 14, 631-640.
200. Hedqvist, P.; Fredholm, B.B. Inhibitory effect of adenosine on adrenergic neuroeffector transmission in the rabbit heart. Acta Physiol. Scand., 1979, 105, 120-122. (Pubitemid 9121327)
201. Gross, G.J.; Hardman, H.F.; Warltier, D.C. Adenosine on myocardial oxygen consumption. Br. J. Pharmacol., 1976, 57, 409-412.
202. Weihprecht, H.; Lorenz, J.N.; Schnermann, J.; Skott, O.; Briggs, J.P. Effect of adenosine1-receptor blockade on renin release from rabbit isolated perfused juxtaglomerular apparatus. J. Clin. Invest., 1990, 85, 1622-1628. (Pubitemid 20176460)
203. Matsuoka, H.; Yamada, K.; Atarashi, K.; Takagi, M.; Sugimoto, T. Role of adenosine A1 and A2 receptors in the regulation of aldosterone production in rat adrenal glands. Experientia, 1990, 46, 726-728. (Pubitemid 20216644)
204. Auchampach, J.A. Adenosine receptors and angiogenesis. Circ. Res., 2007, 101, 1075-1077. (Pubitemid 350146431)
205. Desai, A.; Victor-Vega, C.; Gadangi, S.; Montesinos, M.C.; Chu, C.C.; Cronstein, B.N. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Mol. Pharmacol., 2005, 67, 1406-1413. (Pubitemid 40594139)
206. Tabrizchi, R.; Bedi, S. Pharmacology of adenosine receptors in the vasculature. Pharmacol. Ther., 2001, 91, 133-147. (Pubitemid 33139798)
207. Mullane, K.; Bullough, D. Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosine. J. Mol. Cell. Cardiol., 1995, 27, 1041-1054.
208. Villarreal, F.; Zimmermann, S.; Makhsudova, L.; Montag, A.C.; Erion, M.D.; Bullough, D.A.; Ito, B.R. Modulation of cardiac remodeling by adenosine: In vitro and in vivo effects. Mol. Cell. Biochem., 2003, 251, 17-26. (Pubitemid 37220704)
209. Fredholm, B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ., 2007, 14, 1315-1323. (Pubitemid 46965261)
210. Dubey, R.K.; Gillespie, D.G.; Osaka, K.; Suzuki, F.; Jackson, E.K. Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension, 1996, 27, 786-793.
211. Ryzhov, S.; Zaynagetdinov, R.; Goldstein, A.E.; Novitskiy, S.V.; Dikov, M.M.; Blackburn, M.R.; Biaggioni, I.; Feoktistov, I. Effect of A2B adenosine receptor gene ablation on proinflammatory adenosine signaling in mast cells. J. Immunol., 2008, 180, 7212-7220.
212. Feoktistov, I.; Ryzhov, S.; Goldstein, A.E.; Biaggioni, I. Mast cell-mediated stimulation of angiogenesis: Cooperative interaction between A2B and A3 adenosine receptors. Circ. Res., 2003, 92, 485-492. (Pubitemid 36368660)
213. Feoktistov, I.; Goldstein, A.E.; Ryzhov, S.; Zeng, D.; Belardinelli, L.; Voyno-Yasenetskaya, T.; Biaggioni, I. Differential expression of adenosine receptors in human endothelial cells: Role of A2B receptors in angiogenic factor regulation. Circ. Res., 2002, 90, 531-538. (Pubitemid 34640902)
214. Kin, H.; Zatta, A.J.; Lofye, M.T.; Amerson, B.S.; Halkos, M.E.; Kerendi, F.; Zhao, Z.Q.; Guyton, R.A.; Headrick, J.P.; Vinten-Johansen, J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res., 2005, 67, 124-133. (Pubitemid 40798299)
215. Headrick, J.P.; Hack, B.; Ashton, K.J. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H1797-1818. (Pubitemid 37305920)
216. Gessi, S.; Merighi, S.; Varani, K.; Leung, E.; Mac Lennan, S.; Borea, P.A. The A3 adenosine receptor: An enigmatic player in cell biology. Pharmacol. Ther., 2008, 117, 123-140. (Pubitemid 350192673)
217. Gessi, S.; Fogli, E.; Sacchetto, V.; Merighi, S.; Varani, K.; Preti, D.; Leung, E.; Maclennan, S.; Borea, P.A. Adenosine modulates HIF-1{alpha}, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 90-97.
218. Mahaffey, K.W.; Puma, J.A.; Barbagelata, N.A.; DiCarli, M.F.; Leesar, M.A.; Browne, K.F.; Eisenberg, P.R.; Bolli, R.; Casas, A.C.; Molina- Viamonte, V.; Orlandi, C.; Blevins, R.; Gibbons, R.J.; Califf, R.M.; Granger, C.B. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol., 1999, 34, 1711-1720.
219. Ross, A.M.; Gibbons, R.J.; Stone, G.W.; Kloner, R.A.; Alexander, R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol., 2005, 45, 1775-1780. (Pubitemid 40779856)
220. Lee, C.H.; Low, A.; Tai, B.C.; Co, M.; Chan, M.Y.; Lim, J.; Lim, Y.T.; Tan, H.C. Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: A prospective randomized study. Eur. Heart J., 2007, 28, 19-25. (Pubitemid 46137813)
221. Wei, M.; Kuukasjarvi, P.; Laurikka, J.; Honkonen, E.L.; Kaukinen, S.; Laine, S.; Tarkka, M. Cardioprotective effect of adenosine pretreatment in coronary artery bypass grafting. Chest, 2001, 120, 860-865. (Pubitemid 32885461)
222. Vinten-Johansen, J.; Zhao, Z.Q.; Corvera, J.S.; Morris, C.D.; Budde, J.M.; Thourani, V.H.; Guyton, R.A. Adenosine in myocardial protection in onpump and off-pump cardiac surgery. Ann. Thorac. Surg., 2003, 75, S691- 699. (Pubitemid 36184550)
223. Loffler, M.; Morote-Garcia, J.C.; Eltzschig, S.A.; Coe, I.R.; Eltzschig, H.K. Physiological roles of vascular nucleoside transporters. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 1004-1013. (Pubitemid 46641985)
224. Visser, F.; Vickers, M.F.; Ng, A.M.; Baldwin, S.A.; Young, J.D.; Cass, C.E. Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. J. Biol. Chem., 2002, 277, 395-401. (Pubitemid 34952071)
225. Archer, R.G.; Pitelka, V.; Hammond, J.R. Nucleoside transporter subtype expression and function in rat skeletal muscle microvascular endothelial cells. Br. J. Pharmacol., 2004, 143, 202-214. (Pubitemid 39280040)
226. Saito, H.; Nishimura, M.; Shinano, H.; Makita, H.; Tsujino, I.; Shibuya, E.; Sato, F.; Miyamoto, K.; Kawakami, Y. Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. Am. J. Respir. Crit. Care Med., 1999, 159, 1014-1018. (Pubitemid 29137809)
227. Chaudary, N.; Naydenova, Z.; Shuralyova, I.; Coe, I.R. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc. Res., 2004, 61, 780-788. (Pubitemid 38249477)
228. Buolamwini, L.K. Nucleoside transporter inhibitors: Structure-activity relationship and potential therapeutic applications. Curr. Med. Chem., 1997, 4, 35-66.
229. Leung, G.P.; Man, R.Y.; Tse, C.M. Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells. Biochem. Pharmacol., 2005, 70, 355-362. (Pubitemid 40905107)
230. Wang, C.; Pimple, S.; Buolamwini, J.K. Interaction of benzopyranone derivatives and related compounds with human concentrative nucleoside transporters 1, 2 and 3 heterologously expressed in porcine PK15 nucleoside transporter deficient cells. Structure-activity relationships and determinants of transporter affinity and selectivity. Biochem. Pharmacol., 2010, 79, 307-320.
231. Verma, A.; Marangos, P.J. Nitrobenzylthioinosine binding in brain: An interspecies study. Life Sci., 1985, 36, 283-290. (Pubitemid 15193990)
232. Conant, A.R.; Jarvis, S.M. Nucleoside influx and efflux in guinea-pig ventricular myocytes. Inhibition by analogues of lidoflazine. Biochem. Pharmacol., 1994, 48, 873-880.
233. Zhu, Z.; Hofmann, P.A.; Buolamwini, J.K. Cardioprotective effects of novel tetrahydroisoquinoline analogs of nitrobenzylmercaptopurine riboside in an isolated perfused rat heart model of acute myocardial infarction. Am. J. Physiol. Heart Circ. Physiol., 2007, 292, H2921-2926. (Pubitemid 47084542)
234. Benedict, S.H.; Lin, P.S.; Zwicker, R.D.; Huang, D.T.; Schmidt-Ullrich, R.K. The biological effectiveness of intermittent irradiation as a function of overall treatment time: Development of correction factors for linac-based stereotactic radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1997, 37, 765-769. (Pubitemid 27181306)
235. Elion, G.B. Pharmacologic and physical agents. Immunosuppressive agents. Transplant. Proc., 1977, 9, 975-979.
236. Zhu, Z.; Furr, J.; Buolamwini, J.K. Synthesis and flow cytometric evaluation of novel 1,2,3,4-tetrahydroisoquinoline conformationally constrained analogues of nitrobenzylmercaptopurine riboside (NBMPR) designed for probing its conformation when bound to the es nucleoside transporter. J. Med. Chem., 2003, 46, 831-837. (Pubitemid 36258873)
237. Picano, E.; Ostojic, M.; Sicari, R.; Baroni, M.; Cortigiani, L.; Pingitore, A. Dipyridamole stress echocardiography: State of the art 1996. EPIC (Echo Persantin International Cooperative) Study Group. Eur. Heart J., 1997, 18 Suppl. D, D16-23.
238. Ashrani, A.; Keshavarzian, A.; Jacyno, M.; Winship, D.; Fields, J.Z. Are dipyridamole (sensitive) calcium channels present in esophageal smooth muscle? Life Sci., 1997, 60, PL423-430. (Pubitemid 27235122)
239. Harker, L.A.; Kadatz, R.A. Mechanism of action of dipyridamole. Thromb. Res. Suppl., 1983, 4, 39-46. (Pubitemid 13078094)
240. Dogne, J.M.; de Leval, X.; Benoit, P.; Delarge, J.; Masereel, B.; David, J.L. Recent advances in antiplatelet agents. Curr. Med. Chem., 2002, 9, 577-589. (Pubitemid 34436435)
241. Sakata, K.; Nakamura, T.; Tamekiyo, H.; Obayashi, K.; Ishikawa, J.; Nawada, R.; Yoshida, H.; Shirotani, M. Pseudoxanthoma elasticum with dipyridamole-induced coronary artery spasm: A case report. Jpn. Circ. J., 1999, 63, 806-808. (Pubitemid 29486943)
242. Yoshida, Y.; Hirai, M.; Yamada, T.; Tsuji, Y.; Kondo, T.; Inden, Y.; Akahoshi, M.; Murakami, Y.; Tsuda, M.; Tsuboi, N.; Hirayama, H.; Okamoto, M.; Ito, T.; Saito, H.; Toyama, J. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias : Evidence for cAMPmediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation, 2000, 101, 624-630. (Pubitemid 30094733)
243. Cortigiani, L.; Baroni, M.; Picano, E.; Palmieri, C.; Boni, A.; Ravani, M.; Biagini, A.; Nannini, E. Acute hemodynamic effects of endogenous adenosine in patients with chronic heart failure. Am. Heart J., 1998, 136, 37-42. (Pubitemid 28317864)
244. Strauer, B.E.; Heidland, U.E.; Heintzen, M.P.; Schwartzkopff, B. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance. J. Am. Coll. Cardiol., 1996, 28, 1119-1126. (Pubitemid 26376983)
245. Hegedus, K.; Keresztes, T.; Fekete, I.; Molnar, L. Effect of i.v. dipyridamole on cerebral blood flow, blood pressure, plasma adenosine and cAMP levels in rabbits. J. Neurol. Sci., 1997, 148, 153-161. (Pubitemid 27152180)
246. Lin, W.; Buolamwini, J.K. Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors. J. Med. Chem., 2007, 50, 3906-3920. (Pubitemid 47292054)
247. Brantmark, B.; Egelius, N.; Fabricius, E.; Jemt, M.; Palmborg, G.; Philipson, J.; Ronnegard, N. Lidoflazine: Double-blind trial of a new coronary vasodilator in angina pectoris. Eur. J. Clin. Pharmacol., 1973, 6, 156-162.
248. Miyahara, M.; Imura, O.; Yokoyama, M.; Hoshikawa, K. Lidoflazine as an antiarrhythmic drug. Tohoku J. Exp. Med., 1969, 97, 95-96.
249. Flameng, W.; Daenen, W.; Borgers, M.; Thone, F.; Xhonneux, R.; van de Water, A.; van Belle, H. Cardioprotective effects of lidoflazine during 1-hour normothermic global ischemia. Circulation, 1981, 64, 796-807. (Pubitemid 11030134)
250. Wood, A.J.; Isted, K.; Hynd, J.; Main, M.J.; Noble, M.I.; Parker, J.; Drake- Holland, A.J. Mioflazine, a potentially protective drug against ischaemic damage: A study in dogs. Eur. Heart J., 1985, 6, 695-701. (Pubitemid 15236445)
251. Hammond, J.R. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: Species differences and transporter subtype selectivity. Naunyn Schmiedebergs Arch. Pharmacol., 2000, 361, 373-382. (Pubitemid 30148873)
252. Masuda, M.; Demeulemeester, A.; Chen, C.C.; Hendrikx, M.; Van Belle, H.; Flameng, W. Cardioprotective effects of nucleoside transport inhibition in rabbit hearts. Ann. Thorac. Surg., 1991, 52, 1300-1305.
253. Itoya, M.; Miura, T.; Sakamoto, J.; Urabe, K.; Iimura, O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J. Cardiovasc. Pharmacol., 1994, 24, 846-852. (Pubitemid 24334580)
254. Andersen, K.; Dellborg, M.; Swedberg, K. Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur. J. Clin. Pharmacol., 1996, 51, 7-13. (Pubitemid 26300927)
255. Van Belle, H.G., F.; Wynants, J. Biochemical and functional effects of nucleoside transport inhibition in the isolated cat heart. J. Mol. Cell. Cardiol., 1989, 21, 797-805. (Pubitemid 19225948)
256. Ashton, D.; De Prins, E.; Willems, R.; Van Belle, H.; Wauquier, A. Anticonvulsant action of the nucleoside transport inhibitor, soluflazine, on synaptic and non-synaptic epileptogenesis in the guinea-pig hippocampus. Epilepsy Res., 1988, 2, 65-71. (Pubitemid 18063158)
257. Baer, H.P.; Serignese, V.; Moorji, A.; Van Belle, H. In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn Schmiedebergs Arch. Pharmacol., 1991, 343, 365-369.
258. Deguchi, H.; Takeya, H.; Wada, H.; Gabazza, E.C.; Hayashi, N.; Urano, H.; Suzuki, K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood, 1997, 90, 2345-2356. (Pubitemid 27392718)
259. Noji, T.; Karasawa, A.; Kusaka, H. Adenosine uptake inhibitors. Eur. J. Pharmacol., 2004, 495, 1-16. (Pubitemid 38829385)
260. Cristalli, G.; Costanzi, S.; Lambertucci, C.; Lupidi, G.; Vittori, S.; Volpini, R.; Camaioni, E. Adenosine deaminase: Functional implications and different classes of inhibitors. Med. Res. Rev., 2001, 21, 105-128. (Pubitemid 32185243)
261. Hirschhorn, R.; Ratech, H.; Rubinstein, A.; Papageorgiou, P.; Kesarwala, H.; Gelfand, E.; Roegner-Maniscalco, V. Increased excretion of modified adenine nucleosides by children with adenosine deaminase deficiency. Pediatr. Res., 1982, 16, 362-369. (Pubitemid 12150549)
262. Hall, R.H.; Alam, S.N.; McLennan, B.D. N6-(delta 2-isopentenyl)adenosine: Its conversion to inosine, catalyzed by adenosine aminohydrolases from chicken bone marrow and calf intestinal mucosa. Can. J. Biochem., 1971, 49, 623-630.
263. Ratech, H.; Thorbecke, G.J.; Meredith, G.; Hirschhorn, R. Comparison and possible homology of isozymes of adenosine deaminase in Aves and humans. Enzyme, 1981, 26, 74-84. (Pubitemid 11108190)
264. Ratech, H.; Hirschhorn, R. Serum adenosine deaminase in normals and in a patient with adenosine deaminase deficient-severe combined immunodeficiency. Clin. Chim. Acta, 1981, 115, 341-347. (Pubitemid 11052486)
265. Stancikova, M.; Lukac, J.; Istok, R.; Cristalli, G.; Rovensky, J. Serum adenosine deaminase activity and its isoenzyme pattern in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol., 1998, 16, 583-586. (Pubitemid 28439443)
266. Gakis, C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: Diagnostic and biological role. Eur. Respir. J., 1996, 9, 632-633. (Pubitemid 26167862)
267. Niedzwicki, J.G.; Abernethy, D.R. Structure-activity relationship of ligands of human plasma adenosine deaminase2. Biochem. Pharmacol., 1991, 41, 1615-1624.
268. Franco, R.; Casado, V.; Ciruela, F.; Saura, C.; Mallol, J.; Canela, E.I.; Lluis, C. Cell surface adenosine deaminase: Much more than an ectoenzyme. Prog. Neurobiol., 1997, 52, 283-294. (Pubitemid 27306871)
269. Franco, R.; Valenzuela, A.; Lluis, C.; Blanco, J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol. Rev., 1998, 161, 27-42.
270. Martin, M.; Huguet, J.; Centelles, J.J.; Franco, R. Expression of ectoadenosine deaminase and CD26 in human T cells triggered by the TCR-CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J. Immunol., 1995, 155, 4630-4643.
271. Nagy, J.I.; Yamamoto, T.; Uemura, H.; Schrader, W.P. Adenosine deaminase in rodent median eminence: Detection by antibody to the mouse enzyme and co-localization with adenosine deaminase-complexing protein (CD26). Neuroscience, 1996, 73, 459-471. (Pubitemid 26168803)
272. Saura, C.; Ciruela, F.; Casado, V.; Canela, E.I.; Mallol, J.; Lluis, C.; Franco, R. Adenosine deaminase interacts with A1 adenosine receptors in pig brain cortical membranes. J. Neurochem., 1996, 66, 1675-1682. (Pubitemid 26090570)
273. Herrera, C.; Casado, V.; Ciruela, F.; Schofield, P.; Mallol, J.; Lluis, C.; Franco, R. Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol. Pharmacol., 2001, 59, 127-134. (Pubitemid 32043094)
274. Hashikawa, T.; Hooker, S.W.; Maj, J.G.; Knott-Craig, C.J.; Takedachi, M.; Murakami, S.; Thompson, L.F. Regulation of adenosine receptor engagement by ecto-adenosine deaminase. FASEB J., 2004, 18, 131-133.
275. Ciruela, F.; Saura, C.; Canela, E.I.; Mallol, J.; Lluis, C.; Franco, R. Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett., 1996, 380, 219-223. (Pubitemid 26063938)
276. Pacheco, R.; Martinez-Navio, J.M.; Lejeune, M.; Climent, N.; Oliva, H.; Gatell, J.M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl. Acad. Sci. USA, 2005, 102, 9583-9588. (Pubitemid 40981724)
277. Sarrio, S.; Casado, V.; Escriche, M.; Ciruela, F.; Mallol, J.; Canela, E.I.; Lluis, C.; Franco, R. The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors to form functional modules in the cell membrane. Mol. Cell. Biol., 2000, 20, 5164-5174. (Pubitemid 30431569)
278. Saura, C.A.; Mallol, J.; Canela, E.I.; Lluis, C.; Franco, R. Adenosine deaminase and A1 adenosine receptors internalize together following agonist-induced receptor desensitization. J. Biol. Chem., 1998, 273, 17610-17617. (Pubitemid 28355098)
279. Gines, S.; Ciruela, F.; Burgueno, J.; Casado, V.; Canela, E.I.; Mallol, J.; Lluis, C.; Franco, R. Involvement of caveolin in ligand-induced recruitment and internalization of A(1) adenosine receptor and adenosine deaminase in an epithelial cell line. Mol. Pharmacol., 2001, 59, 1314-1323. (Pubitemid 32381611)
280. Wu, S.Q.; Fu, L.M.; Koke, J.R.; Bittar, N. Contractility, ATP, and creatine phosphate during myocardial ischaemia and reperfusion: The effects of adenosine and inhibition of adenosine catabolism in the dog heart. Cytobios, 1987, 50, 7-12. (Pubitemid 17073286)
281. Dorheim, T.A.; Hoffman, A.; Van Wylen, D.G.; Mentzer, R.M., Jr. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery, 1991, 110, 136-145.
282. Zhu, Q.Y.; Headrick, J.P.; Berne, R.M. Transmural distribution of extracellular purines in isolated guinea pig heart. Proc. Natl. Acad. Sci. USA, 1991, 88, 657-660. (Pubitemid 21915525)
283. Zhu, Q.Y.; Chen, S.G.; Zou, C.M. Protective effects of an adenosine deaminase inhibitor on ischemia-reperfusion injury in isolated perfused rat heart. Am. J. Physiol., 1990, 259, H835-838.
284. Bolling, S.F.; Bies, L.E.; Bove, E.L.; Gallagher, K.P. Augmenting intracellular adenosine improves myocardial recovery. J. Thorac. Cardiovasc. Surg., 1990, 99, 469-474. (Pubitemid 20097773)
285. Headrick, J.P.; Matherne, G.P.; Berne, R.M. Myocardial adenosine formation during hypoxia: Effects of ecto-5'-nucleotidase inhibition. J. Mol. Cell. Cardiol., 1992, 24, 295-303.
286. Mallet, R.T.; Kang, Y.H.; Mukohara, N.; Bunger, R. Use of cytosolic metabolite patterns to estimate free magnesium in normoxic myocardium. Biochim. Biophys. Acta, 1992, 1139, 239-247.
287. Sandhu, G.S.; Burrier, A.C.; Janero, D.R. Adenosine deaminase inhibitors attenuate ischemic injury and preserve energy balance in isolated guinea pig heart. Am. J. Physiol., 1993, 265, H1249-1256. (Pubitemid 23327716)
288. Xia, Y.; Khatchikian, G.; Zweier, J.L. Adenosine deaminase inhibition prevents free radical-mediated injury in the postischemic heart. J. Biol. Chem., 1996, 271, 10096-10102. (Pubitemid 26131569)
289. Bernauer, W. Effect of exogenous adenosine deaminase on arrhythmias and the release of adenine nucleotide catabolites in isolated rat hearts with coronary occlusion and reperfusion. Naunyn Schmiedebergs Arch. Pharmacol., 1991, 344, 544-550.
290. Cohen, E.S.; Law, W.R.; Easington, C.R.; Cruz, K.Q.; Nardulli, B.A.; Balk, R.A.; Parrillo, J.E.; Hollenberg, S.M. Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis. Am. J. Respir. Crit. Care Med., 2002, 166, 16-20. (Pubitemid 34693957)
291. Tang, R.B.; Dong, J.Z.; Liu, X.P.; Ma, C.S. Inflammation and atrial fibrillation: Is Chlamydia pneumoniae a candidate pathogen of atrial fibrillation? Med. Hypotheses, 2006, 67, 462-466. (Pubitemid 43949447)
292. Jackson, E.K.; Koehler, M.; Mi, Z.; Dubey, R.K.; Tofovic, S.P.; Carcillo, J.A.; Jones, G.S. Possible role of adenosine deaminase in vaso-occlusive diseases. J. Hypertens., 1996, 14, 19-29. (Pubitemid 26099513)
293. McClanahan, T.B.; Ignasiak, D.P.; Martin, B.J.; Mertz, T.E.; Gallagher, K.P. Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs. Basic Res. Cardiol., 1995, 90, 176-183.
294. Li, Y.; Kloner, R.A. Adenosine deaminase inhibition is not cardioprotective in the rat. Am. Heart J., 1993, 126, 1293-1298. (Pubitemid 24000022)
295. Willems, L.; Reichelt, M.E.; Molina, J.G.; Sun, C.X.; Chunn, J.L.; Ashton, K.J.; Schnermann, J.; Blackburn, M.R.; Headrick, J.P. Effects of adenosine deaminase and A1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc. Res., 2006, 71, 79-87. (Pubitemid 43849668)
296. Law, W.R. Transgenic approaches to reintegration. Cardiovasc. Res., 2006, 71, 8-9. (Pubitemid 43870061)
297. Sawa, T.; Fukagawa, Y.; Homma, I.; Takeuchi, T.; Umezawa, H. Mode of inhibition of coformycin on adenosine deaminase. J. Antibiot. (Tokyo), 1967, 20, 227-231.
298. Agarwal, R.P.; Spector, T.; Parks, R.E., Jr. Tight-binding inhibitors-IV. Inhibition of adenosine deaminases by various inhibitors. Biochem. Pharmacol., 1977, 26, 359-367. (Pubitemid 8051288)
299. Schramm, V.L.; Baker, D.C. Spontaneous epimerization of (S)- deoxycoformycin and interaction of (R)-deoxycoformycin, (S)- deoxycoformycin, and 8-ketodeoxycoformycin with adenosine deaminase. Biochemistry, 1985, 24, 641-646. (Pubitemid 15142249)
300. Montgomery, J.A.; Thomas, H.J.; Zell, A.L.; Einsphar, H.M.; Bugg, C.E. Study on the inhibition of adenosine deaminase. J. Med. Chem., 1985, 28, 1751-1753.
301. Jackson, R.C.; Leopold, W.R.; Ross, D.A. The biochemical pharmacology of (2'-R)-chloropentostatin, a novel inhibitor of adenosine deaminase. Adv. Enzyme Regul., 1986, 25, 125-139.
302. Schaeffer, H.J.; Schwender, C.F. Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9- (2-hydroxy-3-alkyl)adenines. J. Med. Chem., 1974, 17, 6-8.
303. Kurz, L.C.; Weitkamp, E.; Frieden, C. Adenosine deaminase: Viscosity studies and the mechanism of binding of substrate and of ground- and transition-state analogue inhibitors. Biochemistry, 1987, 26, 3027-3032. (Pubitemid 17087832)
304. Agarwal, R.P.; Parks, R.E., Jr. Adenosine deaminase from human erythrocytes. Methods Enzymol., 1978, 51, 502-507.
305. Bessodes, M.; Bastian, G.; Abushanab, E.; Panzica, R.P.; Berman, S.F.; Marcaccio, E.J., Jr.; Chen, S.F.; Stoeckler, J.D.; Parks, R.E., Jr. Effect of chirality in erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) on adenosine deaminase inhibition. Biochem. Pharmacol., 1982, 31, 879-882. (Pubitemid 12029012)
306. Curtis, M.A.; Varkhedkar, V.; Pragnacharyulu, P.V.; Abushanab, E. Adenosine deaminase inhibitors. Synthesis and biological evaluation of aralkyladenines (ARADS). Bioorg. Med. Chem. Lett., 1998, 8, 1639-1642. (Pubitemid 28341601)
307. Barankiewicz, J.; Danks, A.M.; Abushanab, E.; Makings, L.; Wiemann, T.; Wallis, R.A.; Pragnacharyulu, P.V.; Fox, A.; Marangos, P.J. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J. Pharmacol. Exp. Ther., 1997, 283, 1230-1238. (Pubitemid 28016498)
308. Cristalli, G.; Franchetti, P.; Grifantini, M.; Vittori, S.; Lupidi, G.; Riva, F.; Bordoni, T.; Geroni, C.; Verini, M.A. Adenosine deaminase inhibitors. Synthesis and biological activity of deaza analogues of erythro-9-(2- hydroxy-3-nonyl)adenine. J. Med. Chem., 1988, 31, 390-393. (Pubitemid 18045369)
309. Koch, H.P.; Jager, W.; Groh, U.; Plank, G. In vitro inhibition of adenosine deaminase by flavonoids and related compounds. New insight into the mechanism of action of plant phenolics. Methods Find. Exp. Clin. Pharmacol., 1992, 14, 413-417.
310. Da Settimo, F.; Primofiore, G.; La Motta, C.; Taliani, S.; Simorini, F.; Marini, A.M.; Mugnaini, L.; Lavecchia, A.; Novellino, E.; Tuscano, D.; Martini, C. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo
311. Antonioli, L.; Fornai, M.; Colucci, R.; Ghisu, N.; Da Settimo, F.; Natale, G.; Kastsiuchenka, O.; Duranti, E.; Virdis, A.; Vassalle, C.; La Motta, C.; Mugnaini, L.; Breschi, M.C.; Blandizzi, C.; Del Taca, M. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J. Pharmacol. Exp. Ther., 2007, 322, 435-442. (Pubitemid 47105786)
312. Lee, G.; Lee, S.S.; Kay, K.Y.; Kim, D.W.; Choi, S.; Jun, H.K. Isolation and characterization of a novel adenosine deaminase inhibitor, IADA-7, from Bacillus sp. J-89. J. Enzyme Inhib. Med. Chem., 2009, 24, 59-64.
313. Elalaoui, A.; Divita, G.; Maury, G.; Imbach, J.L.; Goody, R.S. Intrinsic tryptophan fluorescence of bovine liver adenosine kinase, characterization of ligand binding sites and conformational changes. Eur. J. Biochem., 1994, 221, 839-846. (Pubitemid 24128055)
314. Boison, D. Adenosine kinase, epilepsy and stroke: Mechanisms and therapies. Trends Pharmacol. Sci., 2006, 27, 652-658. (Pubitemid 44738092)
315. Mullane, K. Acadesine: The prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc. Res., 1993, 27, 43-47. (Pubitemid 23035664)
316. Morrison, R.R.; Jones, R.; Byford, A.M.; Stell, A.R.; Peart, J.; Headrick, J.P.; Matherne, G.P. Transgenic overexpression of cardiac A(1) adenosine receptors mimics ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2000, 279, H1071-1078.
317. Ely, S.W.; Berne, R.M. Protective effects of adenosine in myocardial ischemia. Circulation, 1992, 85, 893-904.
318. Kroll, K.; Decking, U.K.; Dreikorn, K.; Schrader, J. Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ. Res., 1993, 73, 846-856. (Pubitemid 23306130)
319. Peart, J.; Matherne, G.P.; Cerniway, R.J.; Headrick, J.P. Cardioprotection with adenosine metabolism inhibitors in ischemic-reperfused mouse heart. Cardiovasc. Res., 2001, 52, 120-129. (Pubitemid 32835245)
320. Peart, J.N.; Gross, G.J. Cardioprotection following adenosine kinase inhibition in rat hearts. Basic Res. Cardiol., 2005, 100, 328-336. (Pubitemid 40974083)
321. Willems, L.; Headrick, J.P. Protecting murine hearts from ischaemiareperfusion using selective inhibitors of adenosine metabolism. Clin. Exp. Pharmacol. Physiol., 2005, 32, 179-183. (Pubitemid 40387115)
322. Haines, D.D.; Bak, I.; Ferdinandy, P.; Mahmoud, F.F.; Al-Harbi, S.A.; Blasig, I.E.; Tosaki, A. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts. J. Cardiovasc. Pharmacol., 2000, 35, 37-44. (Pubitemid 30032892)
323. Bochelen, D.; Rudin, M.; Sauter, A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther., 1999, 288, 653-659. (Pubitemid 29119677)
324. Hwang, K.K.; Hall, C.S.; Spielman, W.S.; Sparks, H.V. FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur. J. Pharmacol., 2001, 425, 85-93. (Pubitemid 32739153)
325. Miller, L.P.; Jelovich, L.A.; Yao, L.; DaRe, J.; Ugarkar, B.; Foster, A.C. Preand peristroke treatment with the adenosine kinase inhibitor, 5'- deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett., 1996, 220, 73-76. (Pubitemid 26426587)
326. Tatlisumak, T.; Takano, K.; Carano, R.A.; Miller, L.P.; Foster, A.C.; Fisher, M. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke, 1998, 29, 1952-1958. (Pubitemid 28399997)
327. Jarvis, M.F.; Yu, H.; McGaraughty, S.; Wismer, C.T.; Mikusa, J.; Zhu, C.; Chu, K.; Kohlhaas, K.; Cowart, M.; Lee, C.H.; Stewart, A.O.; Cox, B.F.; Polakowski, J.; Kowaluk, E.A. Analgesic and anti-inflammatory effects of A-286501, a novel orally active adenosine kinase inhibitor. Pain, 2002, 96, 107-118. (Pubitemid 34270633)
328. Firestein, G.S.; Bullough, D.A.; Erion, M.D.; Jimenez, R.; Ramirez- Weinhouse, M.; Barankiewicz, J.; Smith, C.W.; Gruber, H.E.; Mullane, K.M. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J. Immunol., 1995, 154, 326-334.
329. Gu, J.W.; Ito, B.R.; Sartin, A.; Frascogna, N.; Moore, M.; Adair, T.H. Inhibition of adenosine kinase induces expression of VEGF mRNA and protein in myocardial myoblasts. Am. J. Physiol. Heart Circ. Physiol., 2000, 279, H2116-2123.
330. McGaraughty, S.; Cowart, M.; Jarvis, M.F. Recent developments in the discovery of novel adenosine kinase inhibitors: Mechanism of action and therapeutic potential. CNS Drug Rev., 2001, 7, 415-432. (Pubitemid 34263875)
331. Cowart, M.; Lee, C.H.; Gfesser, G.A.; Bayburt, E.K.; Bhagwat, S.S.; Stewart, A.O.; Yu, H.; Kohlhaas, K.L.; McGaraughty, S.; Wismer, C.T.; Mikusa, J.; Zhu, C.; Alexander, K.M.; Jarvis, M.F.; Kowaluk, E.A. Structure-activity studies of 5-substituted pyridopyrimidines as adenosine kinase inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 83-86. (Pubitemid 32006130)
332. Jarvis, M.F.; Yu, H.; Kohlhaas, K.; Alexander, K.; Lee, C.H.; Jiang, M.; Bhagwat, S.S.; Williams, M.; Kowaluk, E.A. ABT-702 (4-amino-5-(3- bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido [2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and antiinflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse. J. Pharmacol. Exp. Ther., 2000, 295, 1156-1164.
333. Matulenko, M.A.; Lee, C.H.; Jiang, M.; Frey, R.R.; Cowart, M.D.; Bayburt, E.K.; Didomenico, S.; Gfesser, G.A.; Gomtsyan, A.; Zheng, G.Z.; McKie, J.A.; Stewart, A.O.; Yu, H.; Kohlhaas, K.L.; Alexander, K.M.; McGaraughty, S.; Wismer, C.T.; Mikusa, J.; Marsh, K.C.; Snyder, R.D.; Diehl, M.S.; Kowaluk, E.A.; Jarvis, M.F.; Bhagwat, S.S. 5-(3- Bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl) pyrido [2,3-d]pyrimidin-4 - ylamine: Structure-activity relationships of 7-substituted heteroaryl analogs as non-nucleoside adenosine kinase inhibitors. Bioorg. Med. Chem., 2005, 13, 3705-3720. (Pubitemid 40615924)
334. Matulenko, M.A.; Paight, E.S.; Frey, R.R.; Gomtsyan, A.; DiDomenico, S., Jr.; Jiang, M.; Lee, C.H.; Stewart, A.O.; Yu, H.; Kohlhaas, K.L.; Alexander, K.M.; McGaraughty, S.; Mikusa, J.; Marsh, K.C.; Muchmore, S.W.; Jakob, C.L.; Kowaluk, E.A.; Jarvis, M.F.; Bhagwat, S.S. 4-amino-5-aryl-6- arylethynylpyrimidines: Structure-activity relationships of non-nucleoside adenosine kinase inhibitors. Bioorg. Med. Chem., 2007, 15, 1586-1605. (Pubitemid 46394068)
335. Kalsi, K.K.; Yuen, A.H.; Rybakowska, I.M.; Johnson, P.H.; Slominska, E.; Birks, E.J.; Kaletha, K.; Yacoub, M.H.; Smolenski, R.T. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation-a potential mechanism of protection in heart failure. Cardiovasc. Res., 2003, 59, 678-684. (Pubitemid 38368684)
336. Fishbein, W.N.; Sabina, R.L.; Ogasawara, N.; Holmes, E.W. Immunologic evidence for three isoforms of AMP deaminase (AMPD) in mature skeletal muscle. Biochim. Biophys. Acta, 1993, 1163, 97-104. (Pubitemid 23116035)
337. Morisaki, T.; Gross, M.; Morisaki, H.; Pongratz, D.; Zollner, N.; Holmes, E.W. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc. Natl. Acad. Sci. USA, 1992, 89, 6457-6461.
338. Anderson, J.L.; Habashi, J.; Carlquist, J.F.; Muhlestein, J.B.; Horne, B.D.; Bair, T.L.; Pearson, R.R.; Hart, N. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J. Am. Coll. Cardiol., 2000, 36, 1248-1252.
339. Yoshino, M.M., K.,. Inhibition of AMP deaminase by alkylsulfonate compounds. Environ. Toxicol. Pharmacol., 1998, 5, 215-217.
340. Kasibhatla, S.R.; Bookser, B.C.; Appleman, J.R.; Probst, G.; Xiao, W.; Fujitaki, J.M.; Erion, M.D. Design, synthesis, and structure-activity relationships of the first highly potent, selective, and bioavailable adenosine 5'-monophosphate deaminase inhibitors. Adv. Exp. Med. Biol., 1998, 431, 849-852.
341. Showalter, H.D.; Putt, S.R.; Borondy, P.E.; Shillis, J.L. Adenosine deaminase inhibitors. Synthesis and biological evaluation of (+/-)-3,6,7,8- tetrahydro-3- [(2-hydroxyethoxy)methyl]imidazo [4,5-d] [1,3]diazepin-8-ol and some selected C-5 homologues of pentostatin. J. Med. Chem., 1983, 26, 1478-1482. (Pubitemid 13020903)
342. Bookser, B.C.; Kasibhatla, S.R.; Erion, M.D. AMP deaminase inhibitors. 4. Further N3-substituted coformycin aglycon analogues: N3-alkylmalonates as ribose 5'-monophosphate mimetics. J. Med. Chem., 2000, 43, 1519-1524. (Pubitemid 30238434)
343. Borkowski, T.; Orlewska, C.; Slominska, E.M.; Yuen, A.; Lipinski, M.; Rybakowska, I.; Foks, H.; Kaletha, K.K.; Yacoub, M.H.; Smolenski, R.T. Pharmacological inhibition of AMP-deaminase in rat cardiac myocytes. Nucleosides Nucleotides Nucleic Acids, 2008, 27, 867-871. (Pubitemid 351948566)
344. Semenza, G.L.; Agani, F.; Booth, G.; Forsythe, J.; Iyer, N.; Jiang, B.H.; Leung, S.; Roe, R.; Wiener, C.; Yu, A. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int., 1997, 51, 553-555. (Pubitemid 27088174)
345. Eckle, T.; Krahn, T.; Grenz, A.; Kohler, D.; Mittelbronn, M.; Ledent, C.; Jacobson, M.A.; Osswald, H.; Thompson, L.F.; Unertl, K.; Eltzschig, H.K. Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation, 2007, 115, 1581-1590. (Pubitemid 46648643)
346. Morabito, L.; Montesinos, M.C.; Schreibman, D.M.; Balter, L.; Thompson, L.F.; Resta, R.; Carlin, G.; Huie, M.A.; Cronstein, B.N. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto- 5'-nucleotidase-mediated conversion of adenine nucleotides. J. Clin. Invest., 1998, 101, 295-300. (Pubitemid 28067325)
347. Kitakaze, M.; Hori, M.; Morioka, T.; Minamino, T.; Takashima, S.; Okazaki, Y.; Node, K.; Komamura, K.; Iwakura, K.; Itoh, T.; et al. Alpha 1- adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation, 1995, 91, 2226-2234.
348. Obata, T.; Yamanaka, Y. Tyramine produces interstitial adenosine-mediated activation of ecto-5'-nucleotidase in rat heart in vivo. Eur. J. Pharmacol., 1999, 374, 25-31. (Pubitemid 29296722)
349. Obata, T.; Kubota, S.; Yamanaka, Y. Histamine increases interstitial adenosine concentration via activation of ecto-5'-nucleotidase in rat hearts in vivo. J. Pharmacol. Exp. Ther., 2001, 298, 71-76. (Pubitemid 32574512)
350. Thompson, L.F.; Eltzschig, H.K.; Ibla, J.C.; Van De Wiele, C.J.; Resta, R.; Morote-Garcia, J.C.; Colgan, S.P. Crucial role for ecto-5'-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med., 2004, 200, 1395-1405. (Pubitemid 39657287)
351. Eltzschig, H.K.; Thompson, L.F.; Karhausen, J.; Cotta, R.J.; Ibla, J.C.; Robson, S.C.; Colgan, S.P. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: Coordination by extracellular nucleotide metabolism. Blood, 2004, 104, 3986-3992. (Pubitemid 39620148)
352. Gruber, H.E.; Hoffer, M.E.; McAllister, D.R.; Laikind, P.K.; Lane, T.A.; Schmid-Schoenbein, G.W.; Engler, R.L. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury. Circulation, 1989, 80, 1400-1411. (Pubitemid 19282530)
353. Zhao, Z.Q.; Williams, M.W.; Sato, H.; Hudspeth, D.A.; McGee, D.S.; Vinten-Johansen, J.; Van Wylen, D.G. Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc. Res., 1995, 29, 495-505.
354. Galinanes, M.; Mullane, K.M.; Bullough, D.; Hearse, D.J. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat. Circulation, 1992, 86, 598-608.
355. Young, M.A.; Mullane, K.M. Progressive cardiac dysfunction with repeated pacing-induced ischemia: Protection by AICA-riboside. Am. J. Physiol., 1991, 261, H1570-1577.
356. Bolli, R. Mechanism of myocardial "stunning". Circulation, 1990, 82, 723-738.
357. Cronstein, B.N.; Eberle, M.A.; Gruber, H.E.; Levin, R.I. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc. Natl. Acad. Sci. USA, 1991, 88, 2441-2445. (Pubitemid 21916433)
358. Galinanes, M.; Zhai, X.; Bullough, D.; Mullane, K.M.; Hearse, D.J. Protection against injury during ischemia and reperfusion by acadesine derivatives GP-1-468 and GP-1-668. Studies in the transplanted rat heart. J. Thorac. Cardiovasc. Surg., 1995, 110, 752-761.
359. Mangano, D.T. Effects of acadesine on myocardial infarction, stroke, and death following surgery. A meta-analysis of the 5 international randomized trials. The Multicenter Study of Perioperative Ischemia (McSPI) Research Group. JAMA, 1997, 277, 325-332. (Pubitemid 27045014)
360. Mangano, D.T.; Miao, Y.; Tudor, I.C.; Dietzel, C. Post-reperfusion myocardial infarction: Long-term survival improvement using adenosine regulation with acadesine. J. Am. Coll. Cardiol., 2006, 48, 206-214. (Pubitemid 43929241)
361. Kurz, M.A.; Bullough, D.A.; Bugge, C.J.; Mullane, K.M.; Young, M.A. Cardioprotection with a novel adenosine regulating agent mediated by intravascular adenosine. Eur. J. Pharmacol., 1997, 322, 211-220. (Pubitemid 27122895)
362. Hale, S.L.; Kloner, R.A. Cardioprotection with adenosine-regulating agent, GP531: Effects on no-reflow, infarct size, and blood flow following ischemia/ reperfusion in the rabbit. J. Cardiovasc. Pharmacol. Ther., 2010, 15, 60-67.
363. Goblyos, A.; Ijzerman, A.P. Allosteric modulation of adenosine receptors. Purinergic Signal., 2009, 5, 51-61.
364. Bruns, R.F.; Fergus, J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol., 1990, 38, 939-949.
365. Mizumura, T.; Auchampach, J.A.; Linden, J.; Bruns, R.F.; Gross, G.J. PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ. Res., 1996, 79, 415-423. (Pubitemid 26276902)
366. Kollias-Baker, C.; Xu, J.; Pelleg, A.; Belardinelli, L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ. Res., 1994, 75, 972-980. (Pubitemid 24351443)
367. Baraldi, P.G.; Zaid, A.N.; Lampronti, I.; Fruttarolo, F.; Pavani, M.G.; Tabrizi, M.A.; Shryock, J.C.; Leung, E.; Romagnoli, R. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. Bioorg. Med. Chem. Lett., 2000, 10, 1953-1957. (Pubitemid 30663348)
368. Tranberg, C.E.; Zickgraf, A.; Giunta, B.N.; Luetjens, H.; Figler, H.; Murphree, L.J.; Falke, R.; Fleischer, H.; Linden, J.; Scammells, P.J.; Olsson, R.A. 2-Amino-3-aroyl-4,5-alkylthiophenes: Agonist allosteric enhancers at human A(1) adenosine receptors. J. Med. Chem., 2002, 45, 382-389. (Pubitemid 34073455)
369. Chordia, M.D.; Murphree, L.J.; Macdonald, T.L.; Linden, J.; Olsson, R.A. 2- Aminothiazoles: A new class of agonist allosteric enhancers of A(1) adenosine receptors. Bioorg. Med. Chem. Lett., 2002, 12, 1563-1566. (Pubitemid 34569243)
370. Gao, Z.G.; Van Muijlwijk-Koezen, J.E.; Chen, A.; Muller, C.E.; Ijzerman, A.P.; Jacobson, K.A. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. Mol. Pharmacol., 2001, 60, 1057-1063. (Pubitemid 33027441)
371. van Galen, P.J.; Nissen, P.; van Wijngaarden, I.; Ap, I.J.; Soudijn, W. 1Himidazo [ 4,5-c]quinolin-4-amines: Novel non-xanthine adenosine antagonists. J. Med. Chem., 1991, 34, 1202-1206.
372. Goblyos, A.; Gao, Z.G.; Brussee, J.; Connestari, R.; Santiago, S.N.; Ye, K.; Ijzerman, A.P.; Jacobson, K.A. Structure-activity relationships of new 1H-imidazo [4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J. Med. Chem., 2006, 49, 3354-3361. (Pubitemid 43830533)
373. Gao, Z.G.; Ye, K.; Goblyos, A.; Ijzerman, A.P.; Jacobson, K.A. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol., 2008, 8, 20.
374. Baraldi, P.G.; Iaconinoto, M.A.; Moorman, A.R.; Carrion, M.D.; Cara, C.L.; Preti, D.; Lopez, O.C.; Fruttarolo, F.; Tabrizi, M.A.; Romagnoli, R. Allosteric enhancers for A1 adenosine receptor. Mini Rev. Med. Chem., 2007, 7, 559-569.
375. Figler, H.; Olsson, R.A.; Linden, J. Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol. Pharmacol., 2003, 64, 1557-1564. (Pubitemid 37532245)
376. Aurelio, L.; Valant, C.; Flynn, B.L.; Sexton, P.M.; Christopoulos, A.; Scammells, P.J. Allosteric modulators of the adenosine A1 receptor: Synthesis and pharmacological evaluation of 4-substituted 2-amino-3- benzoylthiophenes. J. Med. Chem., 2009, 52, 4543-4547.
377. Ellenbogen, K.A.; O'Neill, G.; Prystowsky, E.N.; Camm, J.A.; Meng, L.; Lieu, H.D.; Jerling, M.; Shreeniwas, R.; Belardinelli, L.; Wolff, A.A. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation, 2005, 111, 3202-3208. (Pubitemid 40874990)
378. Klaasse, E.C.; Ijzerman, A.P.; de Grip, W.J.; Beukers, M.W. Internalization and desensitization of adenosine receptors. Purinergic Signal., 2008, 4, 21-37.
379. Jacobson, K.A.; von Lubitz, D.K.; Daly, J.W.; Fredholm, B.B. Adenosine receptor ligands: Differences with acute versus chronic treatment. Trends Pharmacol. Sci., 1996, 17, 108-113. (Pubitemid 26112796)